HIV integrase and HIV reverse transcriptase — Drug Target

All drugs that target HIV integrase and HIV reverse transcriptase — marketed and clinical-stage. Includes 6 drug classes acting on this target.

Drug classes

Antiretroviral combination (integrase inhibitor + NNRTI) · Antiretroviral combination (INSTI + NNRTI) · Antiretroviral combination therapy (INSTI + NNRTI) · Long-acting injectable antiretroviral combination (integrase inhibitor + non-nucleoside reverse transcriptase inhibitor) · Antiretroviral combination (INSTI + NRTI) · Antiretroviral combination (integrase inhibitor + non-nucleoside reverse transcriptase inhibitor)

Marketed (3)

• JULUCA · ViiV Healthcare · Antiretroviral combination (integrase inhibitor + NNRTI) · Infectious Disease / Virology
  JULUCA is a two-drug combination that inhibits HIV integrase and reverse transcriptase to suppress viral replication.
• Cabotegravir LA + Rilpivirine LA · Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia · Antiretroviral combination (INSTI + NNRTI) · Infectious Disease / Virology
  Cabotegravir and rilpivirine are long-acting antiretroviral agents that inhibit HIV integrase and reverse transcriptase, respectively, preventing viral replication.
• CAR · ViiV Healthcare · Antiretroviral combination therapy (INSTI + NNRTI) · Infectious Disease / Virology
  CAR is a combination antiretroviral therapy containing cabotegravir and rilpivirine that suppresses HIV replication by inhibiting integrase and reverse transcriptase.

Phase 3 pipeline (4)

• CAB + RPV · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Long-acting injectable antiretroviral combination (integrase inhibitor + non-nucleoside reverse transcriptase inhibitor) · Infectious Disease / Virology
  CAB + RPV is a long-acting injectable combination of cabotegravir (an integrase inhibitor) and rilpivirine (a non-nucleoside reverse transcriptase inhibitor) that suppresses HIV replication by blocking two critical steps in the viral life cycle.
• Dolutegravir + Lamivudine FDC · ViiV Healthcare · Antiretroviral combination (INSTI + NRTI) · Infectious Disease / Virology
  Dolutegravir inhibits HIV integrase to prevent viral DNA integration into the host genome, while lamivudine inhibits reverse transcriptase to block viral replication.
• CAB LA + RPV LA · ViiV Healthcare · Antiretroviral combination (integrase inhibitor + non-nucleoside reverse transcriptase inhibitor) · Infectious Disease / Virology
  CAB LA and RPV LA are long-acting injectable antiretroviral agents that inhibit HIV reverse transcriptase and integrase to suppress viral replication.
• Cabotegravir, Rilpivirine Drug Combination · University Paris 7 - Denis Diderot · Antiretroviral combination (INSTI + NNRTI) · Infectious Disease / Virology
  This combination inhibits HIV integrase and reverse transcriptase to prevent viral replication and integration into host DNA.